CHICAGO, Aug. 4 /PRNewswire-FirstCall/ -- CytoCore, Inc. announced that Dr. George Gorodeski, the head of CytoCore’s Medical Advisory Board and Chief Scientist has had his most recent paper on the P2X7 biomarker, “The P2X7 Receptor: A Novel Biomarker of Uterine Epithelial Cancers”, accepted for publication by the American Association for Cancer Research Journal: Cancer Epidemiology, Biomarkers & Prevention. The article is scheduled for publication in the October issue and will be available on their web site, http://cebp.aacrjournals.org/, at that time.
Dr. Gorodeski’s first paper on the unique characteristics of the P2X7 receptor was published in the Journal of Biological Chemistry in April and can be viewed at http://www.jbc.org/cgi/reprint/M602999200v1. This current paper discusses the clinical aspects of the P2X7 as a marker for Uterine Epithelial Cancers. The P2X7 is being developed under a license to CytoCore.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com
Certain statements in this release are forward-looking. These statements are based on CytoCore’s current expectations and involve many risks and uncertainties, such as the company’s inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore’s expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore’s current expectation depending upon a number of factors affecting the Company’s business. These factors include, among others, risks and uncertainties detailed in the Company’s periodic public filings with the Securities and Exchange Commission, including but not limited to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Contacts: Patty Briguglio MMI Associates, Inc. 919-233-6600 patty@mmimarketing.com Director Communications Gene Martineau (212)348-1852 ebm@interport.net
CytoCore Inc.
CONTACT: Patty Briguglio of MMI Associates, Inc., +1-919-233-6600, orpatty@mmimarketing.com, for CytoCore Inc.; or Gene Martineau, DirectorCommunications of CytoCore Inc., +1-212-348-1852, or ebm@interport.net
